Compass Therapeutics shed half its stock price this morning as investors digested its bispecific antibody’s failure to hit an ...

Compass Therapeutics Inc. CMPX shares are tumbling on Monday as the company announced results from its COMPANION-002 study, ...

LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, ...

Compass Therapeutics will still submit tovecimig for approval despite the OS miss.

While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.

Shares of Compass Pathways PLC climbed on Friday after the U.S.-listed healthcare group announced a successful follow-up study of a psychedelic drug used to treat major depression in cancer patients.

LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...

Webcast scheduled for Monday, April 27, 2026 at 8:00am ET.BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), ...

AUSTIN, Texas--(BUSINESS WIRE)--Compass Learning, a leader in learning acceleration, released the results of a national study conducted to determine the extent to which the company’s software ...